Ownership and insider activity for Aptevo Therapeutics Inc. (APVO): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company primarily focused on pioneering immunotherapeutic agents for a variety of cancer treatments across the United States. Its foremost investigational drug, APVO436, is a bispecific antibody crafted to engage T-cells, which is currently undergoing a Phase 1b clinical study for acute myeloid leukemia and myelodysplastic syndromes.
Price
| Price | $1.72 |
| Market Cap | $4M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-08-06 | Harsanyi Zsolt | M-Exempt | 400 | $0 |
| 2026-08-06 | Harsanyi Zsolt | M-Exempt | 400 | |
| 2026-08-06 | Lamothe Jeffrey G. | M-Exempt | 961 | $1 |
| 2026-08-06 | Lamothe Jeffrey G. | M-Exempt | 961 | |
| 2026-08-06 | Taylor Daphne | M-Exempt | 638 | $1 |
| 2026-08-06 | Taylor Daphne | M-Exempt | 638 | |
| 2026-08-06 | Kwon SoYoung | M-Exempt | 638 | $1 |
| 2026-08-06 | Kwon SoYoung | M-Exempt | 638 | |
| 2026-08-06 | Huebner Dirk | M-Exempt | 638 | $1 |
| 2026-08-06 | Huebner Dirk | F-InKind | 156 | $635 |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $9.7M | $7.1M | $30.6M | $12.4M | $40.0M | $45.0M | $22.6M | $16.9M | $8.7M | $21.6M |
| Short-term Investments | $44.8M | $73.7M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | $307000 | $2.1M | $5.2M | $7.0M | $2.4M | $3.7M | $2.5M | 0 | 0 | 0 |
| Inventory | $6.6M | $1.0M | $1.8M | $6.1M | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $71.4M | $95.1M | $48.7M | $30.0M | $47.3M | $52.6M | $27.4M | $19.1M | $10.7M | $23.1M |
| Property, Plant & Equipment | $5.9M | $5.8M | $5.2M | $7.7M | $5.5M | $4.0M | $6.8M | $5.8M | $4.9M | $4.1M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | $14.5M | $6.1M | $5.2M | $4.4M | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $91.9M | $117.0M | $67.5M | $53.4M | $53.5M | $56.6M | $34.2M | $24.8M | $15.6M | $27.2M |
| Accounts Payable | $10.5M | $7.3M | $11.7M | $13.0M | 0 | 0 | 0 | 0 | $3.1M | $877000 |
| Short-term Debt | 0 | $3.3M | 0 | $19.9M | $5.0M | $11.7M | $2.0M | 0 | 0 | $866000 |
| Total Current Liabilities | $19.5M | $18.5M | $17.6M | $38.2M | $14.5M | $34.8M | $8.7M | $7.2M | $6.2M | $6.0M |
| Long-term Debt | $18.4M | $15.7M | $19.3M | 0 | $20.1M | $3.7M | $1.5M | 0 | 0 | 0 |
| Total Liabilities | $41.3M | $35.0M | $37.1M | $41.6M | $37.0M | $55.4M | $16.2M | $12.6M | $10.8M | $9.8M |
| Retained Earnings | -$80.7M | -$73.7M | -$127.4M | -$167.9M | -$185.6M | -$214.1M | -$206.0M | -$223.4M | -$247.6M | -$275.1M |
| Total Equity | $50.6M | $82.0M | $30.4M | $11.8M | $16.6M | $1.2M | $18.0M | $12.2M | $4.8M | $17.4M |
| Total Debt | $18.4M | $19.1M | $19.3M | $23.2M | $27.4M | $16.7M | $9.5M | $5.4M | $4.6M | $4.6M |
| Net Debt | -$36.1M | -$61.7M | -$11.4M | $10.7M | -$12.6M | -$28.3M | -$13.1M | -$11.5M | -$4.1M | -$17.0M |
| Working Capital | $51.9M | $76.6M | $31.1M | -$8.2M | $32.7M | $17.8M | $18.7M | $11.8M | $4.5M | $17.0M |
Financial Health
| Debt / Equity | 0.70 |
| Current Ratio | 2.08 |
Profitability
| Return on Equity | -201.49% |
| Return on Invested Capital | -262.30% |
| Return on Assets | -181.89% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ABP · BCDA · CERO · EPIX · ERNA · HCWB · INAB
Explore sector: Healthcare · Biotechnology
More sections of APVO: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks